Alder biopharmaceuticals inc (ALDR)
Income statement / Quarterly
Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Revenues
Collaboration and license agreements

0

0

0

0

0

0

-

-

683

-

-

-

113

-

-

-

-

-

6,436

38,784

4,703

4,782

4,824

4,710

4,663

4,599

Operating expenses
Cost of sales

-

-

-

-

-

-

-

-

683

-

-

-

113

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

34,125

69,589

64,449

47,793

52,818

74,048

44,749

52,188

65,276

90,689

41,789

29,491

33,833

27,647

21,636

22,852

14,088

11,035

9,995

7,047

9,377

7,020

6,334

8,922

8,145

8,482

General and administrative

21,633

44,498

13,325

10,685

11,911

11,553

10,337

8,236

9,548

9,981

7,398

6,239

6,466

6,045

4,793

4,318

3,930

3,677

3,408

3,158

2,736

3,160

2,353

1,859

1,641

1,821

Total operating expenses

55,758

114,087

77,774

58,478

64,729

85,601

56,022

60,424

75,507

100,670

49,187

35,730

40,412

33,692

26,429

27,170

18,018

14,712

13,403

10,205

12,113

10,180

8,687

10,781

9,786

10,303

Gain on license of clazakizumab

-

-

-

-

-

-

-

-

-

-

-

-

1,050

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from operations

-55,758

-114,087

-77,774

-58,478

-64,729

-85,601

-55,086

-60,424

-74,824

-100,670

-49,187

-35,730

-39,249

-33,692

-26,429

-27,170

-18,018

-14,712

-6,967

28,579

-7,410

-5,398

-3,863

-6,071

-5,123

-5,704

Other income (expense)
Interest income

2,492

1,966

2,275

2,458

2,533

1,643

809

763

438

485

473

549

529

415

321

248

74

59

14

18

9

3

7

9

16

22

Interest expense

4,975

4,838

4,863

4,783

4,688

2,851

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Foreign currency gain (loss)

-

-

-

36

-

-

99

231

-113

6

-86

-31

-146

-86

-

-159

289

-

-

-

-

-

-

-

-

-

Other income

-

-

-

-

-

-

-

49

-

-

-

172

-

-

-

84

-

-

-

49

-

-

-

158

-

22

Change in fair value of derivative liability

-200

-975

-

-153

-1,500

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5

40

-

Total other income (expense), net

-2,653

-3,847

-2,315

-2,442

-3,660

-1,208

909

1,043

325

491

387

690

383

329

264

173

363

59

25

67

9

3

-

162

-24

-

Net loss before equity in net loss of unconsolidated entity

-58,411

-117,934

-80,089

-60,920

-68,389

-86,809

-54,177

-59,381

-74,499

-100,179

-48,800

-35,040

-38,866

-33,363

-

-26,997

-

-

-

-

-

-

-

-

-

-

Equity in net loss of unconsolidated entity

-

-

0

0

0

-222

-180

-184

-130

-149

-

-94

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-58,411

-117,934

-80,089

-60,920

-68,389

-87,031

-54,357

-59,565

-74,629

-100,328

-48,891

-35,134

-38,866

-33,363

-26,165

-26,997

-17,655

-14,653

-6,942

28,646

-7,401

-5,395

-3,875

-5,909

-5,147

-5,682

Deemed dividends on convertible preferred stock attributable to accretion of beneficial conversion feature

-

-

0

0

0

29,460

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Dividends on convertible preferred stock

1,480

1,311

1,381

1,279

2,302

1,083

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss applicable to common stockholders

-59,891

-119,245

-81,470

-62,199

-70,691

-117,574

-54,357

-59,565

-74,629

-100,328

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) per share - basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.93

-

-

-

-6.05

-

-

Net income (loss) per share - diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.88

-

-

-

-6.05

-

-

Weighted average number of common shares used in net income (loss) per share - basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

30,805

-

-

-

976

-

-

Weighted average number of common shares used in net income (loss) per share - diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

32,513

-

-

-

976

-

-

Net loss per share applicable to common stockholders - basic and diluted

-0.72

-1.63

-1.19

-0.91

-1.04

-1.73

-0.56

-0.92

-1.48

-1.99

-0.98

-0.70

-0.79

-0.76

-0.63

-0.62

-0.46

-0.40

-

-

-0.40

-5.38

-

-

-5.27

-5.89

Weighted average number of common shares used in net loss per share - basic and diluted

83,479

73,056

68,352

68,232

67,966

67,844

68,039

64,526

50,427

50,395

50,365

50,226

49,284

43,753

43,756

43,525

38,162

36,903

-

-

18,556

1,002

-

-

976

964